Each sachet contains Glucosamine Sulfate Sodium Chloride eq. to Glucosamine Sulfate 1500 mg, Sodium Chloride 384 mg.
Pharmacology: Mechanism of action: Glucosamine enhances cartilage proteoglycan synthesis, thereby inhibiting deterioration of cartilage brought about by osteoarthritis and helping maintain equilibrium between cartilage catabolic and anabolic process. (Proteoglycans are essential component of articular cartilage.)
Pharmacokinetics: Absorption and bioavailability: After oral administration, the gastrointestinal absorption of Glucosamine was close to 90%. However, due to the hepatic first pass effect, the oral bioavailability of Glucosamine was 44%.
Glucosamine incorporates with plasma globulins.
Excretion: Approximately 82% of an orally administered dose of radiolabeled glucosamine is excreted as carbon dioxide in expire air within 144 hours after administration in rat.
Approximately 11% of an orally administered dose of radiolabeled glucosamine sulfate was excreted in feces.
Use in knee osteoarthritis for improvement in symptoms and mobility of joints.
For osteoarthritis: Dissolve 1 sachet with a glass of water. To be taken once daily for at least 4-8 weeks or as directed by the physicians.
Glucosamine is contraindicated in patients who are hypersensitive to this drug.
Long term oral administration of this drug may cause high blood sugar level, therefore should periodically monitor blood glucose when administering this drug.
Diabetes patients, use as prescribed by the physician.
Glucosamine may enhance anti-coagulant activity of warfarin. Patients with combination therapy with glucosamine and warfarin should monitor INR level and be aware of bleeding.
Patients with an allergy to shellfish and shellfish products should avoid administering glucosamine.
Patients with asthma may be at risk for an asthma exacerbation when taking glucosamine-chondroitin sulfate.
Glucosamine should not be taken during pregnancy and lactation because scientific evidence for safe use is not available.
Common adverse effects: Gastrointestinal disturbances including nausea, vomiting, dyspepsia, heartburn, constipation, diarrhea, anorexia, glucose intolerance due to resistance insulin and asthma exacerbation.
Antidiabetic agents, Doxorubicin, Etoposide, Tenoposide: Glucosamine should be avoided in patients being treated with these drugs because glucosamine may reduce drug effectiveness.
Glucosamine may enhance anti-coagulant activity of warfarin.
M01AX05 - glucosamine ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.
Glucotril powd for oral soln 1500 mg
30 × 1's
Sign Out
